(Q39212742)

English

Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties.

scientific article published on 10 January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306863%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306863%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

based on heuristic

inferred from title

Olivier Manches

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306863%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

7

object named as

Nina Bhardwaj

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306863%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Patrick A Ott

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306863%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Trevor Henry

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306863%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Sonja Jimenez Baranda

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306863%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Davor Frleta

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306863%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Dusan Bogunovic

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306863%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

10 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306863%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306863%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

62

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306863%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306863%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

811-822

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306863%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

https://scigraph.springernature.com/pub.10.1007/s00262-012-1389-z

0 references

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Immunosuppressive networks in the tumour environment and their therapeutic relevance

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Regulatory T cells, tumour immunity and immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

B7-H1 pathway and its role in the evasion of tumor immunity.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Improved survival with MEK inhibition in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Tumour-mediated disruption of dendritic cell function: inhibiting the MEK1/2-p44/42 axis restores IL-12 production and Th1-generation.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Extracellular signal-regulated protein kinase signaling pathway negatively regulates the phenotypic and functional maturation of monocyte-derived human dendritic cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Targeting dendritic cell signaling to regulate the response to immunization

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

The role of the p38 mitogen-activated protein kinase, extracellular signal-regulated kinase, and phosphoinositide-3-OH kinase signal transduction pathways in CD40 ligand-induced dendritic cell activation and expansion of virus-specific CD8+ T cell m

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1389-Z

21 January 2018

Identifiers

10.1007/S00262-012-1389-Z

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306863%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306863%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39212742&oldid=1790237429"